In Reply We are aware that the FDA and other agencies may not have approved all of the new oral anticoagulants for the treatment of venous thromboembolism; however, many jurisdictions have. The purpose of Table 1 was not to list drugs that have received agency approval but rather to list drugs that have evidence behind their use.
The PEITHO study1 was not published when we wrote our review (although it has been published since), and we chose not to describe in detail data only available from an abstract. Furthermore, given the complexity and cost of thrombolytic therapy, we focused on mortality as the most likely outcome to affect practice. We acknowledge that the study was positive for the primary end point.
Wells PS, Forgie MA, Rodger MA. Therapies for Venous Thromboembolism—Reply. JAMA. 2014;311(24):2543-2544. doi:10.1001/jama.2014.6123